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NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAlDs) are a class of compounds that continue to be prescribed frequently for both children and adults. It is estimated that more than lOO million prescriptions are written annually for these drugs,I and the number is growing. The NSAIl?s are used commonly for their antiinflammatory, analges1 7 , and antipyretic effects. Their increasing popularity in~di atric practice is reflected by the large number of advertisements touting their beneficial attributes for children and the expanding number of NSAID products avail~ble as palatable liquid formulations. Despite their popu~anty~d overall safety profile, important adverse effects including potential drug-drug interactions do occur with NS.AIDs.2, 3 One clinical dilemma encountered frequently m adults and much less frequently in pediatric practice is the pou:ntial drug-drug interaction between NSAIDs and warfan!1' Clearly, a drug-drug interaction exists between warfarin and most NSAIDs}03,4 Many investigators have expended tremendous amounts of time and resources performing elegantly designed studies to assess mechanism(s) an~the clinical significance of this interaction."?~?~ever, 8 reported a 13-fold increased risk of developing hemorrhagic ulcer disease in elderly patients receiving combined warfarin-NSAIDs as compared with nonusers of either drug. This increased risk in patients more than 65 years of age compares with a 2.2-fold risk for hospitalization because of peptic ulcer in elderly patients receiving oral anticoagulant therapy.
In this issue of The Annals Chan provides an exhaustive review of the consequences of combined warfarin-NSAID therapy. This review complements other recent publications l ,5,7,9 questioning the universal recommendations against combined NSAID administration and highlights the complexity of this drug-drug interaction. The old adage that coadministration of warfarin and NSAIDs is an absolute contraindication is slowly and appropriately fading, As described by Chan, certain NSAIDs, when administered concomitantly with warfarin, can potentiate the anticoagulant effect of warfarin through either pharmacokinetic and/or pharmacodynamic interactions.v" Although the literature regarding these interactions often is conflicting and sometimes confusing, NSAIDs have been shown to interact with warfarin via 2 distinct pathways: (1) displacement of warfarin from albumin binding sites, and (2) interference with warfarin body clearance (CI), Most NSAIDs can displace warfarin to some degree from albumin binding sites. I ,3,5,7 Unfortunately, the clinical significance or lack of significance of such a displacement interaction is often misunderstood. A simple protein displacement interaction involving warfarin is associated with a transient increase in the amount of free, active warfarin, This increase in free warfarin concentration appears to be associated with only a temporary enhancement of anticoagulant effeet," Within approximately 10 days of a warfarin-NSAID displacement interaction, a new warfarin steady-state concentration is achieved between warfarin body stores and drug ClP Although the fraction of free, unbound warfarin in serum is increased, the total serum warfarin concentration is decreased because of the more rapid CI of the unbound moiety. Once new steady-state concentrations are achieved. the overall net effectof these opposingprocesses isthe maintenance of equivalent free serum warfarinconcentrations with an equivalent warfarin anticoagulant effect as observed before the addition of the displacer drug."
The incidence and number of therapeutic agents involved in clinically significant protein binding displacement interactions appears to be few. 7,IO.12 This low incidence in the face of a large number of possible protein binding drug displacement interactions with commonly used drugs accounts for some of the confusion by clinicians regarding the clinical significance of these interactions. As stated previously. the initial increase in the free serum drugconcentration thatoccurs immediately afterintroduction of a displacing agent graduallydeclines to predisplacement steady-state values after redistribution occurs. Thus. the important variable underscoring true clinical significance is the duration of the redistribution process. which is influenced directly by the pharmacokinetic parameters volumeof distribution (Vd) and Cl. Clinically important exaggerated pharmacodynamic effect following a simple protein binding displacementinteraction would be expectedfor only thosedrugs with a smallV d «0.25 Lkg), prolonged elimination half-life (tIn). and a narrow therapeutic index." Warfarin. a drug with a small V d (0.1 Ukg), prolonged tIn, and narrow therapeutic index. is a classic compound for such reactions.
Considering the pharmacokinetic characteristics of warfarin (i.e.•reduced V d and prolonged tIn). initialdosage adjustments would appear prudent wheneveran NSAID and warfarin are to be used concomitantly. Actual dosing strategies would depend on the patientand the patient's specific need. Patients stabilized on warfarin who require an NSAID could have their warfarin dosage empirically reduced temporarily and adjusted on the basis of frequent international normalized ratio (lNR) determinations (e.g.• weekly until stabilized). or preferably. as suggested by Chan.the NSAIDcould beadded at a reduceddosage with gradual dosage escalation while maintaining the warfarin dosage constant. again with close monitoring of the INR. Such a strategy has been suggested for aspirin. I of the oldest NSAIDs, as a reduced-dose aspirin-warfarin combination for patients after acute myocardial infarction." Such clinical scenarios requiring the combined use of NSAIDs and warfarin often occur in patients with thromboembolic disorders or autoimmune or rheumatoid diseases; these drugs can be coadministered safely in the same patient. I,5,7,8,14 Althoughthe INR may be an effective means to target and monitor warfarin therapy. patients must be advised and monitored carefully for any signs of bleeding when this therapeutic combination is used.
In addition to and possibly magnifying the effects of a drug-drug proteindisplacement interaction is the potential for I drug to influence the CI of another, As reviewed by Chan. the classicstudies with phenylbutazone identified an important stereochemical drug interaction between this NSAID and warfarin.s" Commercially available warfarin is a racemic mixture. The anticoagulant activity of the Senantiomer is approximately 5 times more potent than that of the Renantiomer, and the Rand S-enantiomers are metabolized via different pathways. Lewis et al. 6 evaluated the mechanism of the phenylbutazone-warfarin interaction in 5 healthy adults. These investigators found that after a single dose of warfarin in subjects receiving phenylbutazone, the CI of the S-enantiomer was decreased. whereas the CI of the less potent Renantiomer increased. The net effectof these disparate values was an unchanged CI of the racemate from control. Banfield et al." confirmed these findings and described an increase in the free concentrations of both warfarin enantiomers in plasma with coadministered phenylbutazone. This later finding suggests that phenylbutazoneinterference with warfarin CI is stereoselective, whereas displacement from albumin binding sites is not. Although these'-" and other studiesv' define the combined mechanism of the phenylbutazone-warfarin interaction, extrapolation of these findings and, thus. the clinical significance of this interaction relative to other NSAIDsis limitedas it appearsto occur only with phenylbutazone, a drug that rarely is used in clinical medicine currently. To our knowledge, no data exist regarding similar stereoselective metabolic interactions by other NSAIDs with warfarin.
In his review. Chan details additional clinically important variables that directly impact on a decision to coadminister NSAIDs and warfarin. that is. NSAID-associated hypoprothrombinemia. antiplatelet effects. and gastrointestinal irritation/ulceration. Early studies with salicylate suggested a possible aspirin-associated hypoprothrombinemic effect." The mechanism of this possible pharmacologic effect is unknown. though it has been postulated to be caused by salicylate interference with hepatic synthesisof vitamin K-dependentclotting factors. The clinical significance of this possibleeffect is unknown and would appear of only cursory importance, consideringthe large number of individuals who consume salicylate without affecting the clotting cascade. Furthermore. as reviewed by Chan. this may occur more frequently in adults who consume large daily doses of aspirin (~6 g/d) . In contrast. a more important effect of NSAIDs is their influence on platelet aggregation. Most NSAIDs possess the potential to interfere to varying degrees with platelet aggregation.1,5,17 Although aspirin irreversibly binds to platelets. thereby inhibiting function for the lifespan of the platelet, the influence of other NSAIDs on platelet activity appears transient. The clinical significanceof this reversible inhibition of platelet aggregation by nonaspirin NSAIDs is poorly understood. This lack of appreciation for this potentially therapeutic effect of NSAIDs has not been studied adequately in NSAID-warfarin investigations. Studies evaluating nabumetone have demonstrated differences in antiplatelet activity between various NSAIDs.17 Whetherthis difference in effecton plateletaggregation is a dose-related effect or a unique characteristic of this drug. or both. remains to be determined.
One additional important physiologic effect of the NSAID class of drugs that can markedlyinfluencethe decision for concurrent anticoagulant therapy is their propensity to cause gastrointestinal (GI) ulceration.s"Chan shows that most if not all NSAIDscause some degreeof GI irritation and many have been associated with the development of ulcers. Obviously, ulcer formation in an anticoagulated patient can lead to serious and life-threatening bleeding," Although it is difficultto quantitate specificallythe ulcerproducing potentialof specific NSAIDs. relative compar-isons have been proposed. Caruso and Porro" endoscopically evaluated 249 patients with rheumatoid arthritis or osteoarthritis who were receiving NSAIDs. These investigators described an incidence of gastric erosions in 177patients receiving NSAID monotherapy and described the following approximate relationships: aspirin> indometha-cin~ketoprofen~naproxen > diclofenac~ibuprofenõ xyphenbutazone> sulindac~diflunisal. In general, aspirin, phenylbutazone, naproxen, tolmetin, and indomethacin are consideredto cause clinically importantGI irritation frequently, whereas otherNSAIDs appearto possess a lower potential, including the nonacetylated salicylates. Nevertheless, GI bleeding is an important complication in any patient receiving anticoagulant therapy, and safeguards mustbe instituted in any patient receiving the combination. Some clinics frequently prescribe concomitant cytoprotective therapy (e.g., misoprostol) or other GI medications (antacids, histaminej-antagonists) for their patients receiving warfarin and an NSAID.t
One final noteof caution involves patients whoseconditions are stabilized while receiving warfarin therapy and who receive intermittenttherapy (e.g., as needed dosing) with an NSAIDor who topically applyexcessive amounts of NSAID-containing ointments, for example, methyl salicylate, to the skin. NSAID-containing medications are becomingmore widelyavailable withouta prescription with newer analogs petitioning for over-the-counter status. Intermittent, uncontrolled excessive use of these over-thecounterdrugscouldresultin dramatic fluctuations in a patient's INR control and increase the possibilityof gastric erosion. Furthermore, many over-the-counter medications such as medicated rubs and sports rubs contain methyl salicylate, and with aggressive application, amounts sufficient to interact with warfarin can be systemically absorbed. Chow et al. 20 described a woman taking warfarin whose condition was stabilized who presented with multiple bruises, a significantly prolonged INR, and a bloodsalicylate concentration of 2.5 mmol/L after 2 weeks of topical application of an ointment containing methyl salicylate. In a subsequent communication, these authors'! described 11 patientsreceivingwarfarinwho applied methylsalicylate ointment liberally for 2 weeks. All 11 patients exhibited an enhanced INR and all had measurable salicylate concentrations in their blood. Three of these patients had bleeding manifestations possibly resulting from thisinteraction.
Thus, the question seems to persist: Can NSAIDs be coadministered safely with warfarin? Chan provides detailedrecommendations in response to thisimportant question. Weagree with Chan and believethe answerfrom the data reviewed is yes, but as with all drug therapy, the dosages should be individualized to specific patient needs with carefully defined monitoring parameters prospectively identified to assess efficacy and to ensuresafety. If needed,'preferred choices of NSAIDs for coadministration with warfarin would appear to include ibuprofen or nabumetone, and possibly naproxenor tolmetin. To better define the true benefit and risks associated with their use, more controlled experience with warfarin and NSAIDcombinations is clearly needed. Although studies performed in healthy volunteers provide some information about the clinical significance of suchpossible interactions, morede-Warfarin and NSAlDs tailed studies performed in patients chronicallyreceiving these medications (and others) are required to formulate definitive recommendations reflective of clinicalpractice. Until these data are available, pharmacists should recognize that this drug combination does not represent an absolute contraindication and counsel their patients receiving combined therapy as to early signs of bleeding(e.g., easy bruisability, hematuria, blood in the stool), the potential dangers of concurrent alcohol consumption, and the need to be careful with overzealous use of over-the-counter oral and/ortopical NSAIDs.R eferences
